Gilead Asks the FDA to Rescind Orphan Drug Designation for Remdesivir as a Treatment for COVID-19

Gilead Asks the FDA to Rescind Orphan Drug Designation for Remdesivir as a Treatment for COVID-19

Source: 
Motley Fool
snippet: 

Gilead Sciences (NASDAQ: GILD) has asked the Food and Drug Administration to rescind the orphan drug designation it was awarded for remdesivir as a treatment for COVID-19, the disease caused by the new coronavirus.